ERBB2 and neoplasm: The 99mTc-labelled HER2-binding ZHER2:2395 (having a KVDC chelating sequence at the C-terminus) demonstrated an excellent targeting specificity and high imaging contrast of HER2 expression (tumor-to-blood ratio 121 ± 24, 4 h after injection) in a murine model [16].